Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | GRK5 | P34947 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893051 | 0.87 | DAPK3 (0.41) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL3228644 | 0.85 | KMT2A (0.45) | MAPK1ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL3228381 | 0.82 | DAPK3 (0.42) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL3232631 | 0.80 | DAPK3 (0.40) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL3228711 | 0.76 | MAPK1 (0.46) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL3240638 | 0.75 | SMN1; SMN2 (0.34) | NPSR1ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL3231306 | 0.73 | MAPK1 (0.56) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL23214476 | 0.68 | NPSR1 (0.36) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL9316963 | 0.68 | KDM4E (0.36) | ALOX15KDM4EGAA | |
| SCHEMBL13940734 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312305-A1 | Imidazoles as Gaba- B Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | claimed |
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20080312305-A1 | Imidazoles as Gaba- B Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312305-A1 | Imidazoles as Gaba- B Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312305-A1 | Imidazoles as Gaba- B Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007073299-A1 | IMIDAZOLES AS GABA-B RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023704-A1 | Novel Compounds 737 | GRPR, GABRB1, GABBR1 | DAPK3 3680/4885JAK2 3598/4885PRKD3 1907/4885 |
| US-20080312305-A1 | Imidazoles as Gaba- B Receptor Modulators | GABRB1, GABBR2, GABRB2 | DAPK3 3486/4885JAK2 2952/4885PRKD3 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.